Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innoviva, Inc. (NASDAQ: INVA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Innoviva is a diversified healthcare holding company with a royalties portfolio linked to GSK respiratory products, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic healthcare investments.
In its SEC reports, Innoviva discusses royalty revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, net product sales from therapies such as GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the performance of its strategic investment portfolio. Current reports on Form 8-K, for example, furnish quarterly earnings press releases that detail revenue composition, income from operations, changes in fair values of equity and long-term investments, and balance sheet metrics.
For investors following Innoviva’s infectious disease and critical care focus, periodic filings also provide context on regulatory milestones and development programs, such as the New Drug Application for zoliflodacin and its QIDP designation. Proxy statements and related documents can offer additional insight into governance, equity compensation, and capital allocation policies, while registration statements and prospectuses may describe financing activities.
On Stock Titan, each Innoviva filing is accompanied by AI-powered summaries designed to highlight key points, such as changes in royalty streams, trends in IST net product sales, significant investments or licensing transactions, and updates to risk factors. Users can quickly scan recent 10-Q and 10-K reports, review 8-K announcements, and examine Form 4 insider transaction filings to understand how executives and directors are trading INVA shares. Real-time integration with EDGAR helps ensure that new Innoviva filings appear promptly, while AI-generated overviews make dense regulatory documents more accessible to both individual and professional investors.
Innoviva, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025. The amendment is made to comply with Rule 3-09 of Regulation S-X and updates the exhibits section to add separate financial information for an equity investee.
The filing includes the Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. as of December 31, 2025 and 2024 and for the years then ended, along with the related consent from Armata’s independent registered public accounting firm, Ernst & Young LLP. It also provides new certifications from Innoviva’s principal executive and principal financial officers.
The amendment states that, apart from these added exhibits and certifications, all disclosures remain unchanged from the original Annual Report. As of June 30, 2025, the aggregate market value of Innoviva’s common equity held by non‑affiliates was $1.26 billion, and on February 13, 2026, 74,073,646 shares of common stock were outstanding.
Innoviva Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating that, following an internal realignment on January 12, 2026, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing reports 0 shares beneficially owned (0% of the class) of Innoviva common stock. The filing lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration dated 03/27/2026.
Innoviva, Inc. is asking stockholders to vote at its May 4, 2026 annual meeting on corporate governance, pay, auditors and a major new equity plan. Investors will elect five directors, cast an advisory Say-On-Pay vote and consider ratifying Deloitte & Touche LLP as auditor for 2026.
A key item is approval of the 2026 Equity Incentive Plan, reserving 9,000,000 shares of common stock, about 10% of fully diluted shares as of March 9, 2026, to support future stock-based compensation and contingent grants to executives and employees. The proxy highlights strong 2025 results, including net income of $3.30 per diluted share, roughly $645 million in cash and receivables, over $75 million invested in healthcare opportunities and a new $125 million share repurchase program.
Innoviva reported strong growth for 2025, with total revenue rising to $411.3M from $358.7M and net income jumping to $271.2M from $23.4M. Fourth quarter 2025 revenue was $114.6M and net income was $164.2M.
The core royalties portfolio generated $250.3M of 2025 revenue, while Innoviva Specialty Therapeutics delivered U.S. net product sales of $119.2M, up 47% year over year. Cash and cash equivalents increased to $550.9M, supported by $196.9M in operating cash flow. The company highlighted U.S. FDA approval of NUZOLVENCE, the mid‑2025 U.S. launch of ZEVTERA, and initiated a $125M share repurchase program, while indicating an expectation of at least $150M in IST U.S. net product sales in 2026.
Innoviva, Inc. filed its annual report outlining its evolution from a pure royalty business into a diversified biopharmaceutical company. It earns royalties from GSK’s respiratory drugs RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, with tiered rates up to 15% of global net sales.
The company now runs a hospital-focused critical care and infectious disease platform anchored by five FDA-approved products: GIAPREZA®, XACDURO®, XERAVA®, ZEVTERA® and NUZOLVENCE®. These treat severe conditions such as septic shock, carbapenem-resistant Acinetobacter infections, complicated intra-abdominal infections, serious bacterial pneumonias and uncomplicated gonorrhea.
Innoviva highlights regulatory exclusivity, including QIDP designations and extended market protection periods, and notes active competition from numerous branded and generic antibiotics. It also emphasizes disciplined capital deployment, strategic stakes in other healthcare companies and a strategy focused on high unmet medical needs.
Innoviva, Inc. Chief Financial Officer Stephen Basso reported a tax-related share disposition. On February 20, 2026, 1,244 shares of common stock were withheld by the company at $23.39 per share to satisfy income tax obligations on vesting equity awards. After this withholding, Basso directly owns 50,013 shares of Innoviva common stock.
Innoviva, Inc. Chief Executive Officer Pavel Raifeld reported a tax-related share disposition. On the vesting of previously granted equity, 2,986 shares of common stock were withheld by the company at $23.39 per share to cover income tax obligations. After this withholding transaction, Raifeld directly owned 159,290 shares of Innoviva common stock.
Innoviva, Inc. Chief Accounting Officer Marianne Zhen reported a routine tax-related share disposition. On February 20, 2026, 2,460 shares of common stock were withheld at $23.39 per share to cover income tax obligations tied to vesting of prior equity grants, leaving her with 45,877 directly owned shares.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reported a significant ownership stake in Innoviva, Inc. common stock. As of 12/31/2025, they beneficially owned 4,210,172 shares, representing 5.63% of the outstanding common stock, with sole voting and dispositive power over these shares.
The firms state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Innoviva. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these shares.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of 4,360,401 shares of Innoviva Inc. common stock, representing 5.8% of the class as of 12/31/2025. Dimensional reports sole voting power over 4,255,642 shares and sole dispositive power over 4,360,401 shares.
The shares are held by a series of funds and accounts it advises or manages, and Dimensional states that all securities are owned by these funds. Dimensional disclaims beneficial ownership of the securities beyond what is required for Section 13(d) reporting. It also certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva.